Corrigendum to "Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials" [Int. Immunopharmacol. 62 (2018) 46-58].